Snast I, et al. - This systematic review was performed to assess the efficacy and safety of biologic agents in atopic dermatitis (AD). Currently the only biologic with robust evidence of efficacy in AD was dupilumab. Nemolizumab, lebrikizumab, and tralokinumab indicated promise but further data were needed. Longer follow-up and larger studies would establish their safety profile.